Monday, June 06, 2005 1:21:17 PM
You said;...
Gabriel has specifically stated that Ovanome does not yet meet DNAP standards and is not yet ready for the FDA. That means, in no uncertain terms, that the product does not yet meet it's own design requirements.
If 95% is the design goal, perhaps they can't meet that level of accuracy, or perhaps they can meet it but not in a reliable and repeatable manner. Whatever the obstacle, the company has clearly stated it's status. It does not yet meet it's requirements and therefore is not ready for the FDA.
Sooooo FROG....
Lets be VERY CLEAR HERE...
They have a product that has a 96% success rate....
They, with the help of Moffit are under going a clinical study as we speak....
We can expect results and issuance to the FDA in or around 6 to 9 months....
DNAP's ONLY obstacle to date was the $1,000 per patient....
To perform the OVA test....
It seems that this obstacle has been overcome.....
They are ready....
VERY VERY READY---GEO
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM